A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study
Abstract Background Neurodegeneration with brain iron accumulation (NBIA) is a group of genetic neurological disorders frequently associated with iron accumulation in the basal nuclei of the brain characterized by progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and reti...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Online Access: | https://doi.org/10.1186/s13023-024-03453-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850064454287360000 |
|---|---|
| author | Alessandra Pereira Carolina Fischinger Moura de Souza Mónica Álvarez-Córdoba Diana Reche-López José Antonio Sánchez-Alcázar |
| author_facet | Alessandra Pereira Carolina Fischinger Moura de Souza Mónica Álvarez-Córdoba Diana Reche-López José Antonio Sánchez-Alcázar |
| author_sort | Alessandra Pereira |
| collection | DOAJ |
| description | Abstract Background Neurodegeneration with brain iron accumulation (NBIA) is a group of genetic neurological disorders frequently associated with iron accumulation in the basal nuclei of the brain characterized by progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and retinal degeneration or optic nerve atrophy. Pantothenate kinase-associated neurodegeneration (PKAN) is one of the most widespread NBIA disorders. The diagnosis of PKAN is established with clinical features and the “eye of the tiger” sign identified on brain MRI and the identification of biallelic pantothenate kinase 2 (PANK2) pathogenic variants on molecular genetic testing. PANK2 catalyzes the first reaction of coenzyme A (CoA) biosynthesis, thus, altered PANK2 activity is expected to induce CoA deficiency as well as low levels of essential metabolic intermediates such as 4′-phosphopantetheine which is a necessary cofactor for critical proteins involved in cytosolic and mitochondrial pathways such as fatty acid biosynthesis, mitochondrial respiratory complex I assembly and lysine and tetrahydrofolate metabolism, among other metabolic processes. Methods In this manuscript, we examined the effect of a multitarget complex supplements (pantothenate, pantethine, omega-3 and vitamin E) on in vitro patient-derived cellular models and the clinical outcome of the adjuvant supplements in combination with the baseline neurological medication in three PKAN patients. Results Multitarget complex supplements significantly reduced iron accumulation and increased PANK2 and ACP expression levels in the cellular models derived from all three PKAN patients. In addition, the adjunct treatment to the standard neurological medication improved or stabilized the clinical symptoms of patients. Conclusions Our results suggest that multitarget complex supplements can be clinically useful as augmentation therapy for PKAN patients harboring pathogenic variants with residual enzyme levels. Trial registration: CAAE: 58219522.6.0000.5330. Registered 25 May 2022—Retrospectively registered, https://plataformabrasil.saude.gov.br/visao/pesquisador/gerirPesquisa/gerirPesquisaAgrupador.jsf . |
| format | Article |
| id | doaj-art-b5f3fc269cea43328feb2f0759a68405 |
| institution | DOAJ |
| issn | 1750-1172 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Orphanet Journal of Rare Diseases |
| spelling | doaj-art-b5f3fc269cea43328feb2f0759a684052025-08-20T02:49:18ZengBMCOrphanet Journal of Rare Diseases1750-11722024-11-0119111610.1186/s13023-024-03453-xA therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot studyAlessandra Pereira0Carolina Fischinger Moura de Souza1Mónica Álvarez-Córdoba2Diana Reche-López3José Antonio Sánchez-Alcázar4Pediatrics Service, Hospital Moinhos de VentoMedical Genetics Service, Hospital de Clínicas de Porto Alegre, Casa Dos RarosAndalusian Centre for Developmental Biology-CSIC-Pablo de Olavide UniversityAndalusian Centre for Developmental Biology-CSIC-Pablo de Olavide UniversityAndalusian Centre for Developmental Biology-CSIC-Pablo de Olavide UniversityAbstract Background Neurodegeneration with brain iron accumulation (NBIA) is a group of genetic neurological disorders frequently associated with iron accumulation in the basal nuclei of the brain characterized by progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and retinal degeneration or optic nerve atrophy. Pantothenate kinase-associated neurodegeneration (PKAN) is one of the most widespread NBIA disorders. The diagnosis of PKAN is established with clinical features and the “eye of the tiger” sign identified on brain MRI and the identification of biallelic pantothenate kinase 2 (PANK2) pathogenic variants on molecular genetic testing. PANK2 catalyzes the first reaction of coenzyme A (CoA) biosynthesis, thus, altered PANK2 activity is expected to induce CoA deficiency as well as low levels of essential metabolic intermediates such as 4′-phosphopantetheine which is a necessary cofactor for critical proteins involved in cytosolic and mitochondrial pathways such as fatty acid biosynthesis, mitochondrial respiratory complex I assembly and lysine and tetrahydrofolate metabolism, among other metabolic processes. Methods In this manuscript, we examined the effect of a multitarget complex supplements (pantothenate, pantethine, omega-3 and vitamin E) on in vitro patient-derived cellular models and the clinical outcome of the adjuvant supplements in combination with the baseline neurological medication in three PKAN patients. Results Multitarget complex supplements significantly reduced iron accumulation and increased PANK2 and ACP expression levels in the cellular models derived from all three PKAN patients. In addition, the adjunct treatment to the standard neurological medication improved or stabilized the clinical symptoms of patients. Conclusions Our results suggest that multitarget complex supplements can be clinically useful as augmentation therapy for PKAN patients harboring pathogenic variants with residual enzyme levels. Trial registration: CAAE: 58219522.6.0000.5330. Registered 25 May 2022—Retrospectively registered, https://plataformabrasil.saude.gov.br/visao/pesquisador/gerirPesquisa/gerirPesquisaAgrupador.jsf .https://doi.org/10.1186/s13023-024-03453-x |
| spellingShingle | Alessandra Pereira Carolina Fischinger Moura de Souza Mónica Álvarez-Córdoba Diana Reche-López José Antonio Sánchez-Alcázar A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study Orphanet Journal of Rare Diseases |
| title | A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study |
| title_full | A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study |
| title_fullStr | A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study |
| title_full_unstemmed | A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study |
| title_short | A therapeutic approach to pantothenate kinase associated neurodegeneration: a pilot study |
| title_sort | therapeutic approach to pantothenate kinase associated neurodegeneration a pilot study |
| url | https://doi.org/10.1186/s13023-024-03453-x |
| work_keys_str_mv | AT alessandrapereira atherapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT carolinafischingermouradesouza atherapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT monicaalvarezcordoba atherapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT dianarechelopez atherapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT joseantoniosanchezalcazar atherapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT alessandrapereira therapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT carolinafischingermouradesouza therapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT monicaalvarezcordoba therapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT dianarechelopez therapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy AT joseantoniosanchezalcazar therapeuticapproachtopantothenatekinaseassociatedneurodegenerationapilotstudy |